Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin
- PMID: 17324959
- DOI: 10.1093/jac/dkl539
Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin
Abstract
Objectives: Successful treatment of infections involving multiply drug-resistant methicillin-resistant Staphylococcus aureus (MRSA) is becoming increasingly difficult. In this work, we have investigated the potential of combining lysostaphin with cationic antimicrobial peptides to effectively inhibit Staphylococcus aureus.
Methods: S. aureus strains were grown in 96-well plates in the presence of increasing concentrations of lysostaphin and the peptides ranalexin, dermaseptin S3(1-16) or magainin 2. Growth was determined visually after 48 h and the plates imaged, or by automated optical density readings in a plate reader. Susceptibility to the combination of lysostaphin and ranalexin was also determined by viable cell counts. The efficacy of combined lysostaphin and ranalexin on a solid surface was tested via disc diffusion assays.
Results and conclusions: Combination of lysostaphin with ranalexin resulted in potent, synergistic inhibition of S. aureus MSSA476 and MRSA252. Synergistic inhibition was specific for lysostaphin-susceptible staphylococci and was not observed with clinical isolates of the Gram-negative Escherichia coli, or other Gram-positive organisms, such as Enterococcus faecalis. Lysostaphin was not specifically synergistic with ranalexin alone. Synergy was also observed with two other cationic antimicrobial peptides, magainin 2 and dermaseptin s3(1-16); although combination with ranalexin was most potent. Synergistic inhibition by ranalexin in combination with lysostaphin resulted in an enhanced bactericidal effect. Importantly, synergy between lysostaphin and ranalexin was also observed after impregnation and drying in filter paper discs that clearly inhibited growth of S. aureus on the surface of agar; a solid, porous matrix. Thus, the combination could represent a novel route to target wounds infected with drug-resistant MRSA via dressings impregnated with the two compounds.
Similar articles
-
In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.Int J Antimicrob Agents. 2010 Jun;35(6):559-65. doi: 10.1016/j.ijantimicag.2010.01.016. Epub 2010 Mar 4. Int J Antimicrob Agents. 2010. PMID: 20206480
-
Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA).J Appl Microbiol. 2010 Feb;108(2):723-30. doi: 10.1111/j.1365-2672.2009.04472.x. Epub 2009 Jul 13. J Appl Microbiol. 2010. PMID: 19709343
-
MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin.J Antimicrob Chemother. 2013 Nov;68(11):2569-75. doi: 10.1093/jac/dkt243. Epub 2013 Jun 25. J Antimicrob Chemother. 2013. PMID: 23800902
-
Lysostaphin: an antistaphylococcal agent.Appl Microbiol Biotechnol. 2008 Sep;80(4):555-61. doi: 10.1007/s00253-008-1579-y. Epub 2008 Jul 8. Appl Microbiol Biotechnol. 2008. PMID: 18607587 Review.
-
Key considerations in the treatment of complicated staphylococcal infections.Clin Microbiol Infect. 2008 Mar;14 Suppl 2:3-9. doi: 10.1111/j.1469-0691.2008.01923.x. Clin Microbiol Infect. 2008. PMID: 18226084 Review.
Cited by
-
Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands.Appl Environ Microbiol. 2012 Apr;78(7):2297-305. doi: 10.1128/AEM.07050-11. Epub 2012 Jan 27. Appl Environ Microbiol. 2012. PMID: 22286996 Free PMC article.
-
Synergistic action of antimicrobial peptides and antibiotics: current understanding and future directions.Front Microbiol. 2024 Jul 31;15:1390765. doi: 10.3389/fmicb.2024.1390765. eCollection 2024. Front Microbiol. 2024. PMID: 39144233 Free PMC article. Review.
-
Antimicrobial Effect of a Peptide Containing Novel Oral Spray on Streptococcus mutans.Biomed Res Int. 2020 Mar 10;2020:6853652. doi: 10.1155/2020/6853652. eCollection 2020. Biomed Res Int. 2020. PMID: 32258136 Free PMC article.
-
Chimeric Peptidoglycan Hydrolases Kill Staphylococcal Mastitis Isolates in Raw Milk and within Bovine Mammary Gland Epithelial Cells.Viruses. 2022 Dec 15;14(12):2801. doi: 10.3390/v14122801. Viruses. 2022. PMID: 36560804 Free PMC article.
-
Antimicrobial activity of bacteriophage derived triple fusion protein against Staphylococcus aureus.AIMS Microbiol. 2019 Jun 25;5(2):158-175. doi: 10.3934/microbiol.2019.2.158. eCollection 2019. AIMS Microbiol. 2019. PMID: 31384710 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical